论文部分内容阅读
目的比较恩替卡韦联合护肝布祖热颗粒治疗维吾尔族、汉族慢性乙型肝炎患者的临床疗效。方法采取前瞻性、配对研究方法,选取2015年1月至2015年5月新疆和田地区传染病医院就诊的初始治疗的慢性乙型肝炎患者为试验组,维吾尔族:汉族按照4:1配对分组,维吾尔族300例,汉族75例,均接受恩替卡韦联合护肝布祖热颗粒治疗12周,随机抽取20例汉族慢性乙型肝炎患者与80例维吾尔族慢性乙型肝炎患者为对照组,仅使用恩替卡韦治疗12周。观察各组患者病毒学应答率、血清学应答率、生物化学应答率以及不良反应发生率。结果治疗4周、8周、12周病毒完全应答率分别为:试验组中维吾尔族9.0%、20.7%、30.3%,汉族8.0%、21.3%、29.3%,对照组中维吾尔族2.5%、12.5%、21.3%,汉族5.0%、10.0%、20.0%;部分应答率分别为:试验组中维吾尔族48.3%、64.3%、69.3%,汉族46.7%、62.7%、64.0%,对照组中维吾尔族46.3%、62.5%、66.3%,汉族45.0%、65.0%、65.0%;生化学应答率分别为:试验组中维吾尔族88.7%、94.7%、99.3%,汉族85.3%、90.6%、98.6%,对照组中维吾尔族83.8%、87.5%、96.3%,汉族85.0%、90.0%、95.0%;血清学应答率分别为:试验组中维吾尔族31.7%、汉族29.3%、对照组中维吾尔族和汉族均为45.0%。治疗前后各组患者均未见明显脏器功能损伤。结论恩替卡韦联合护肝布祖热颗粒治疗维吾尔族慢性乙型肝炎患者的疗效比治疗汉族慢性乙型肝炎患者的疗效更好。
Objective To compare the clinical efficacy of entecavir with Huganpuzuju Granule in the treatment of patients with chronic hepatitis B from Uygur and Han nationality. Methods A prospective and matched study was conducted to select the patients with chronic hepatitis B who were treated initially at the Infectious Diseases Hospital of Hotan, Xinjiang from January 2015 to May 2015 as the experimental group. The Uygur and Han nationality were divided into 4 groups according to 4: 1, 300 Uygur nationality and 75 Han nationality patients were enrolled for treatment of entecavir combined with Bupivu heat particles for 12 weeks. 20 Han patients with chronic hepatitis B and 80 Uygur patients with chronic hepatitis B were randomly selected as the control group. Only entecavir Treatment for 12 weeks. The virological response rate, serological response rate, biochemical response rate and incidence of adverse reactions in each group were observed. Results The complete response rates of virus at 4 weeks, 8 weeks and 12 weeks of treatment were respectively 9.0%, 20.7%, 30.3% in Uygur nationality group, 8.0% in Han nationality, 21.3% in Han nationality, 29.3% in Uygur nationality group, 2.5% %, 21.3% in Han nationality, 5.0% in Han nationality, 10.0% in Han nationality, and 20.0% in Han nationality. The partial response rates were 48.3%, 64.3% and 69.3% in Uygur nationality group, 46.7%, 62.7% and 64.0% in Han nationality, 46.3%, 62.5%, 66.3%, Han 45.0%, 65.0%, 65.0%. The biochemical response rates were 88.7%, 94.7% and 99.3% in the Uygur group, 85.3%, 90.6% and 98.6% In the control group, 83.8%, 87.5% and 96.3% of the Uygur nationality, 85.0%, 90.0% and 95.0% of the Han nationality respectively. The serological response rate was 31.7% in the Uigur group and 29.3% in the Han nationality in the experimental group. The Uygur and Han nationality in the control group All were 45.0%. Before and after treatment, no obvious organ dysfunction was found in all the patients. Conclusion Efficacy of entecavir combined with BUPT on Uygur patients with chronic hepatitis B is better than that of patients with chronic hepatitis B from Han nationality.